Related Experiment Video
Updated: Jul 6, 2026
07:29
Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
Published on: October 12, 2017
Myeloperoxidase gene sequence variations are associated with low-density-lipoprotein characteristics
Guillaume Dolley1,2,3, Benoit Lamarche2,3, Jean-Pierre Després4,5
1CRML, CHUL Research Center, 2705 Laurier Blvd, Quebec, G1V-4G2, Canada.
Journal of Human Genetics
|March 7, 2008
Summary
Genetic variations in the myeloperoxidase (MPO) gene were investigated for their link to low-density lipoprotein particle size. While MPO gene variants did not significantly affect LDL particle size, one polymorphism was associated with lower LDL cholesterol levels.
Area of Science:
- Genetics
- Cardiovascular Disease Research
- Biochemistry
Background:
- Small, dense low-density-lipoprotein (LDL) is linked to increased atherosclerosis risk.
- A genome-wide scan identified a quantitative trait locus (QTL) for LDL peak-particle size (LDL-PPD) on chromosome 17q21, which contains the myeloperoxidase (MPO) gene.
- MPO's ability to oxidize LDL suggests a potential role in LDL metabolism and atherosclerosis.
Purpose of the Study:
- To investigate the association between MPO gene polymorphisms and LDL-PPD.
- To examine the relationship between MPO gene variants and plasma lipid levels.
- To identify novel genetic variants within the MPO gene.
Main Methods:
- Direct sequencing of MPO gene coding, splicing, and regulatory regions in 25 subjects.
- Genotyping of 680 subjects from the Quebec Family Study (QFS) using TaqMan or direct sequencing.
- Measurement of LDL-PPD using gradient gel electrophoresis (GGE).
Main Results:
- Sixteen MPO gene polymorphisms were identified.
- The c.-653G > A MPO polymorphism was significantly associated with lower plasma total cholesterol, LDL cholesterol (LDL-C), and LDL apolipoprotein B (LDL-apoB) levels.
- No significant association was found between MPO gene variants and LDL-PPD, nor a gene-dosage effect on LDL-PPD.
Conclusions:
- MPO gene variants are unlikely to be the cause of the QTL for LDL-PPD on 17q21.
- The c.-653G > A MPO polymorphism is associated with reduced plasma LDL-C and LDL-apoB concentrations.
- Further research may explore the role of MPO in lipid metabolism independent of LDL particle size.
Related Concept Videos
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:27Protein Import into the Peroxisomes
Cells contain membrane-bound organelles called peroxisomes that oxidize organic molecules by transferring hydrogen atoms to oxygen, producing hydrogen peroxide. Peroxisomes enzymatically convert the released hydrogen peroxide into water and oxygen.
Peroxisomal Protein Import:
Peroxisomes lack the genetic machinery required to code for their own proteins. Hence, most peroxisomal membrane, lumenal and transmembrane proteins are synthesized in the cytoplasm or ER and transported to the peroxisome...
Peroxisomal Protein Import:
Peroxisomes lack the genetic machinery required to code for their own proteins. Hence, most peroxisomal membrane, lumenal and transmembrane proteins are synthesized in the cytoplasm or ER and transported to the peroxisome...
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
02:32Exon Recombination
The evolution of new genes is critical for speciation. Exon recombination, also known as exon shuffling or domain shuffling, is an important means of new gene formation. It is observed across vertebrates, invertebrates, and in some plants such as potatoes and sunflowers. During exon recombination, exons from the same or different genes recombine and produce new exon-intron combinations, which might evolve into new genes.
Exon shuffling follows “splice frame rules.” Each exon has three reading...
Exon shuffling follows “splice frame rules.” Each exon has three reading...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...